Aggressive Bone Metastases in Urachal Carcinoma

Mohanti, B.K.; Kumar, Lalit; Biswal, Biswa Mohan; Lal, Pranay; Rath, Goura Kishor; Padhy, Ajit Kumar; Vijayaraghavan, M; Sharma, Mansi

doi:10.1159/000282897

Cited by 5 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gemcitabine/cisplatin chemotherapy has been reported to treat recurrent and metastatic urachal adenocarcinoma with some success [9]. Shin Ebara reported a good case of gemcitabine/cisplatin/ paclitaxel (GCP) regiment not only as a salvage chemotherapy but also as a rechallenge regimen for metastatic urachal cancer including a neuroendocrine component [10].…”

Section: Discussionmentioning

confidence: 99%

A Case of Metastatic Urachal Carcinoma Treated with Palliative Chemotherapy with Gemcitabine and Cisplatin

Li¹,

Chen²,

Guan³

et al. 2017

Med Surg Urol

View full text Add to dashboard Cite

Urachal carcinoma is a rare, non-urothelial carcinoma that represents less than one percent of all bladder cancers. We present a case of a 48-year-old man who presented metastatic urachal carcinoma with intermittent abdominal pain and a poor Performance Status (PS). The patient initially underwent two cycles of XELOX-P (Oxaliplatin/Xeloda/Paclitaxel) chemotherapy after his initial salvage surgery. He came to our hospital for tumor progression and badly abdominal pain. He then received Gemcitabine and Cisplatin (GC) regimen at 80% of the dose with good tolerance and manageable toxicities. After six cycles of chemotherapy, he had a stable disease response, including impressive clinical response on medical symptoms and minor shrinkage of tumor mass on imaging. This case suggests the importance of palliative chemotherapy of GC regimen for the metastatic urachal cancer patients, and that performance status alone should not be limiting decision factors for cancer patients.

show abstract